Targeted Drug Delivery through Conjugation

With more than 30 years of experience in bio-conjugation, SAFC has become a leading expert for the conjugation of highly active molecules.

Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugation technology uses monoclonal antibodies or other biologics to deliver conjugated Highly-Active Pharmaceutical Ingredients (HAPIs) to targeted cells. In conjugated form, the HAPI exhibits more selective cytotoxicity, thereby, sparing non-target cells from many of the toxic effects. Customers are quickly adapting these complex technologies and employing them to develop new oncology products that are more targeted and exponentially more powerful.

Our offer includes:

  • Development and manufacture of commercial scale HAPIs, linkers, cytotoxic agents and conjugates
  • Suite dedicated to conjugation of HAPIs to biologic molecules
  • Working with the market leaders in linker technology
  • Conjugation of non-potent APIs to biologic carriers, including proteins, polyamino acids or polynucleotides
  • Extensive analytical tests for APIs and biological assays
  • Commercial suite coming online in 2015

Comprehensive Solutions

SAFC & Baxter’s BioPharma Solutions business (BPS), two of the leading contract manufacturing organizations in the ADC space, are now offering a combined approach for your ADC to simplify the supply chain and provide comprehensive, coordinated and collaborative services for the development, manufacturing, and testing of bulk drug substance and drug product. Together we offer a full range of services needed for ADCs:

  • Conjugation
  • Linkers and cytotoxic agents
  • Formulation development   
  • Fill/finish including lyophilization
  • Process development
  • Technology transfer
  • Analytical method development and validation
  • Stability studies for bulk drug substance and drug product
Contact SAFC

Contract Manufacturing Inquiries
For product/service inquiries, quotes or information requests

Contact our ADC experts directly at conjugation@sial.com